WINTON GROUP Ltd Sells 229,317 Shares of Exelixis, Inc. (NASDAQ:EXEL)

WINTON GROUP Ltd decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 85.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,536 shares of the biotechnology company's stock after selling 229,317 shares during the period. WINTON GROUP Ltd's holdings in Exelixis were worth $1,317,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Principal Securities Inc. grew its position in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the last quarter. USA Financial Formulas bought a new stake in shares of Exelixis during the fourth quarter worth $32,000. Kestra Investment Management LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at $39,000. UMB Bank n.a. raised its holdings in shares of Exelixis by 68.4% in the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after buying an additional 553 shares during the last quarter. Finally, Crowley Wealth Management Inc. bought a new stake in Exelixis during the 4th quarter worth about $50,000. Institutional investors own 85.27% of the company's stock.

Exelixis Stock Down 0.4 %

Shares of EXEL traded down $0.17 on Tuesday, hitting $36.75. The company's stock had a trading volume of 511,031 shares, compared to its average volume of 2,136,750. The firm has a market capitalization of $10.29 billion, a price-to-earnings ratio of 20.77, a P/E/G ratio of 1.13 and a beta of 0.57. The firm's fifty day moving average price is $35.72 and its 200-day moving average price is $33.39. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Mary C. Beckerle sold 12,210 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock valued at $5,177,234. Company insiders own 2.85% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 19th. Oppenheimer lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. BMO Capital Markets lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and increased their price objective for the company from $36.00 to $40.00 in a report on Friday, December 20th. Bank of America lowered shares of Exelixis from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. Finally, Barclays increased their price target on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.